CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 345 enrolled
Drug / intervention
Juvéderm® VOLUMA XCdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00978042
NCT00978042N/ACompleted

Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation

Allergan·interventional·Posted Sep 16, 2009·Updated Nov 3, 2015

In Brief

A clinical study evaluating Juvéderm® VOLUMA XC for Mid-facial Volume Deficit Related to Aging. Completed, enrolled 345 participants across 2 sites in 2 countries.

Detailed Summary

Multicenter, single-blind, randomized, "no-treatment" control study to demonstrate the safety and effectiveness of VOLUMA XC for deep injection for cheek augmentation to correct age-related volume deficit in the mid-face.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 16, 2009
Enrollment StartAug 1, 2009
Primary CompletionNov 1, 2012
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 16.8 years ago

Interventions

Juvéderm® VOLUMA XCdevice

Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.